Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Sea level doesn’t rise at the same rate everywhere – we mapped where Antarctica’s ice melt would have the biggest impact - 2Sydney Sweeney is returning in 'The Housemaid's Secret': What to know about 'The Housemaid' sequel
- 3Watch This Glacier Race into the Sea
- 4We analyzed Philly street scenes and identified signs of gentrification using machine learning trained on longtime residents’ observations
- 5Human evolution’s biggest mystery has started to unravel. How 2025 tipped the scales
- French Senate debates social media ban for under-15s
- Select Your Go-To Bluetooth Earphones
- ChatGPT served as "suicide coach" in man's death, lawsuit alleges
- Yemen's Houthis ready to join Iran war if needed, raising new shipping risk
- Sound Maturing: Wellbeing Tips for Each Life Stage
- Egypt's cafés and shops forced to close early due to Iran war
- Step by step instructions to Protect Your Retirement with Senior Protection.
- The most effective method to Pick the Ideal Lab Precious stone Wedding band
- 'Backward and upward and tilted': Spaceflight causes astronauts' brains to shift inside their skulls
